Belite Bio - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
HomeBelite Bio
Belite Bio logo

Belite Bio

0 followers

BLTE

Performance

About Belite Bio

Belite Bio is a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal degenerative diseases with significant unmet medical needs. The company’s lead candidate, Tinlarebant (LBS-008), is an oral therapy derived from its RBP4 IP portfolio and aims to reduce toxin accumulation in the eye to address geographic atrophy and Stargardt disease. Belite Bio has advanced Tinlarebant through Phase 2 in adolescent STGD1 and is conducting Phase 3 (DRAGON) and Phase 2/3 (DRAGON II) trials in STGD1, as well as Phase 3 (PHOENIX) in GA, with multiple designations including Orphan Drug, Rare Pediatric Disease, Breakthrough Therapy, and Fast Track. Headquartered in San Diego, California, the company pursues therapies to treat blinding retinal conditions and related metabolic diseases.

Recent News

No recent news for this company.

Recent Deals

No recent deals for this company.

Key Team Members

Tom Lin

Chairman, CEO

Nathan Mata

Chief Scientific Officer (CSO)

Key Facts

HQ Location

San Diego, United States

Founded

2018

Employees

Unknown

Status

Public

Website

https://belitebio.com